PH24525A - New use of bromocriptine - Google Patents

New use of bromocriptine

Info

Publication number
PH24525A
PH24525A PH35534A PH35534A PH24525A PH 24525 A PH24525 A PH 24525A PH 35534 A PH35534 A PH 35534A PH 35534 A PH35534 A PH 35534A PH 24525 A PH24525 A PH 24525A
Authority
PH
Philippines
Prior art keywords
bromocriptine
new use
new
Prior art date
Application number
PH35534A
Other languages
English (en)
Inventor
Douglas Larson
Peter Hiestand
Original Assignee
Sandoz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ltd filed Critical Sandoz Ltd
Publication of PH24525A publication Critical patent/PH24525A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH35534A 1986-07-14 1987-07-14 New use of bromocriptine PH24525A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88511086A 1986-07-14 1986-07-14

Publications (1)

Publication Number Publication Date
PH24525A true PH24525A (en) 1990-07-18

Family

ID=25386156

Family Applications (1)

Application Number Title Priority Date Filing Date
PH35534A PH24525A (en) 1986-07-14 1987-07-14 New use of bromocriptine

Country Status (13)

Country Link
JP (1) JPS6323817A ( )
KR (1) KR880001292A ( )
AU (1) AU602154B2 ( )
CH (1) CH672987A5 ( )
DE (1) DE3722383A1 ( )
DK (1) DK363887A ( )
FR (1) FR2601245A1 ( )
GB (1) GB2192541B ( )
IT (1) IT1224222B ( )
NL (1) NL8701631A ( )
PH (1) PH24525A ( )
SE (1) SE8702843L ( )
ZA (1) ZA875145B ( )

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3814521A1 (de) * 1987-05-07 1988-11-17 Sandoz Ag Neue anwendung von dopaminrezeptor-agonisten
EP0327040A3 (de) * 1988-02-05 1990-11-28 Predrag Dr.Sc. Sikiric Verwendung von Dopamin und/oder von Dopamin-Agonisten zur Herstellung eines Arzneimittels für die Behandlung des Verdauungstrakts
US5716933A (en) * 1988-05-10 1998-02-10 Louisiana State University And Agricultural And Mechanical College Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates
US6004972A (en) * 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5744477A (en) * 1988-05-10 1998-04-28 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for treatment of obesity using prolactin modulators and diet
US5668155A (en) * 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US5700800A (en) * 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5585347A (en) * 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US5830895A (en) * 1988-05-10 1998-11-03 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for the determination and adjustment of prolactin daily rhythms
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
WO1993012793A1 (en) * 1991-12-23 1993-07-08 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College A therapeutic process for the treatment of the pathologies of type ii diabetes
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
US5626860A (en) * 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US5714519A (en) * 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
PT2091537E (pt) 2006-11-23 2013-08-29 Sinoxa Pharma Gmbh Composições farmacêuticas para o tratamento da arteriopatia capilar
DK3445362T3 (da) * 2016-04-20 2021-10-11 Veroscience Llc Sammensætning og fremgangsmåde til behandling af stofskiftesygdomme
EP4233913A3 (en) 2017-10-18 2023-10-18 VeroScience LLC Improved bromocriptine formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
CH666406A5 (de) * 1984-02-29 1988-07-29 Sandoz Ag Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten.
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions

Also Published As

Publication number Publication date
CH672987A5 ( ) 1990-01-31
ZA875145B (en) 1989-02-22
SE8702843L (sv) 1988-01-15
KR880001292A (ko) 1988-04-22
IT8748160A0 (it) 1987-07-10
SE8702843D0 (sv) 1987-07-13
NL8701631A (nl) 1988-02-01
DK363887D0 (da) 1987-07-13
IT1224222B (it) 1990-09-26
FR2601245A1 (fr) 1988-01-15
DE3722383A1 (de) 1988-01-28
GB8716323D0 (en) 1987-08-19
GB2192541B (en) 1990-05-02
JPS6323817A (ja) 1988-02-01
AU7558787A (en) 1988-01-21
GB2192541A (en) 1988-01-20
DK363887A (da) 1988-01-15
AU602154B2 (en) 1990-10-04

Similar Documents

Publication Publication Date Title
GB2192541B (en) New use of bromocriptine
YU46588A (en) Process for obtaining new derivtives of indolyzine
GB8703394D0 (en) Determination of basic values
GB8509322D0 (en) Determination of microconstituent
IL76781A0 (en) Occular formulation comprising bromocriptine
GB8616696D0 (en) Kit of parts
GB8726942D0 (en) Slip structure of timepiece
GB8629658D0 (en) Indicating condition of surface
GB2217729B (en) Obtenation of scualane
GB8727401D0 (en) Preparation of trifluoromethylbenzonitrile
GB8511623D0 (en) Heteroanalogs of imidazobenzodiazepines
IL78611A0 (en) Production of polyprenoid and ubiquinone-type compounds
PH20347A (en) New use of dihydroergotamine
GB2196961B (en) Preparation of polyfluoroenolates
ZA883237B (en) Use of dopaminereceptor agonists
IE871875L (en) New use of bromocriptine
GB8601724D0 (en) Application of tetracyano-quinodimethanes
GB2189391B (en) Use of chemical compounds
ZA889365B (en) Hydrates of andinotropic agent
GB8602313D0 (en) Reduction of photo-yellowing
ZA884990B (en) New use of 5-ht3-antagonists
EP0154940A3 (en) Use of somatostatin
GB8628710D0 (en) Piegon of piece
GB8704561D0 (en) Application of tetrathiafulvalenes
IE882090L (en) New use of 5-ht3-antagonists